NCT07466901 2026-03-12
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Fudan University
Phase NA Not yet recruiting
Clinical Trials
21 trialsNCT05772273 2025-11-21
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase NA Recruiting
NCT06061276 2024-09-23
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Sun Yat-sen University
Phase NA Recruiting
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation
NCT05202314 2023-02-21
NACSOC-02
Beijing Chao Yang Hospital
Phase NA Recruiting
NCT05697237 2023-01-25
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT04420130 2022-10-04
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
Harbin Medical University
Phase NA Withdrawn
NCT05532527 2022-09-08
NSCLC
Henan Provincial People's Hospital
Phase NA Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT04675866 2022-04-15
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
Henan Cancer Hospital
Phase NA Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT04654403 2021-08-23
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Phase NA Unknown
NCT04950400 2021-07-06
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
Beijing Chest Hospital
Phase NA Unknown
NCT04889768 2021-05-17
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
Zhejiang Cancer Hospital
Phase NA Unknown
NCT04507750 2020-09-21
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
Qianfoshan Hospital
Phase NA Unknown
NCT03222440 2019-12-04
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Completed
NCT04174339 2019-11-22
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase NA Unknown
NCT03914352 2019-04-16
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Cancer Hospital of Guangxi Medical University
Phase NA Unknown
NCT03671265 2019-01-09
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03722875 2018-12-19
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
Phase NA Unknown